The MSCI ACWI IMI Genomic Innovation Index, developed in collaboration with ARK Invest, is based on the MSCI ACWI IMI Index, its parent index, and includes large, mid and small-cap securities across 23 Developed Markets (DM) and 26 Emerging Markets (EM) countries. The Index aims to represent the performance of a set of companies that are expected to derive significant revenues, based on the underlying index methodology criteria, from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology.
The Index includes companies from the parent universe which are determined to have high exposure to business activities such gene editing, agricultural biotechnology, molecular diagnostics, genome related hardware for analytics and diagnostics, bioinformatics, targeted therapeutics, gene and stem cell therapies.
For this data source, RIMES hosts approximately 200 companies and 1 index (ACWI IMI Genomic Innovation).
Some of the data items available from this source include the following:
Get in touch. We can source specific data, just for you.